In this PharmaPhorum article, authors Lev Gerlovin and Pascale Diesel conducted an analysis of recent activity in the biotechnology sector to better understand deal-making trends related to cell and gene therapies. They reviewed more than 30 mergers, acquisitions, and licensing agreements executed between 2016-2019 and compared them to deals that were executed for the previous generation of breakthrough therapies, including monoclonal antibodies (mAbs).
In this analysis, the authors considered a range of factors including the size of the companies involved, target indications, deal structures, terms such as upfront payments and royalties, and the number and clinical stage of assets included in each deal.
The authors acknowledge the contributions of Súil Collins and Alex David.
Click the link below to read the article.
Strategic implications for the 340B Rebate Model Pilot Program
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...